Operating Company Healthcare

Biosynth

Staad, St. Gallen, Switzerland

Critical raw materials and services for diagnostics, vaccines and pharmaceuticals. Expertise across complex chemicals, peptides and key biologics, with global distribution and manufacturing/custom synthesis capabilities to de-risk customers’ supply chains.

Focus Areas
Complex chemicals, Peptides, Bioconjugation

Tracked deals

7

7 tracked deals across 2022-2023.

Recent pace

0

0 tracked deals announced in the last 12 months.

Deal mix

Addon

4 addon · 2 buyout · 1 divestiture

Biosynth Acquisition Volume by Year

Last 2 years

Acquisition volume by year Annual acquisition counts for the last 2 years for Biosynth. 3 2022 4 2023

Supporting Data

Recent Transactions

  • Biosynth Acquires Pepceuticals to Add Multi-Kilogram GMP Peptide Manufacturing
    September 25, 2023
    Buyer
    Biosynth
    Target
    Pepceuticals
    Industry
    Pharmaceuticals
    Location
    United Kingdom
    Type
    Addon

    Biosynth has acquired Pepceuticals, a UK-based specialist in synthetic peptides with multi-kilogram GMP and fill-finish capabilities. The deal expands Biosynth’s peptide division and enables end-to-end support from discovery through clinical trials to commercial supply.

  • Biosynth Acquires celares to Expand Bioconjugation and Polymer Drug Delivery Capabilities
    July 11, 2023
    Buyer
    Biosynth
    Target
    celares GmbH
    Industry
    Biotechnology
    Location
    Berlin, Germany
    Type
    Buyout

    Biosynth, a Switzerland-based supplier of critical raw materials and manufacturing services, acquired Berlin-based celares, a developer and manufacturer of bioconjugates, activated PEGs and polymer-based drug delivery excipients. The acquisition strengthens Biosynth's capabilities in conjugate vaccines and bioconjugate drugs and adds GMP bioconjugation and PEGylation manufacturing in Berlin to its service offering.

  • Biosynth Acquires Cambridge Research Biochemicals (CRB)
    May 9, 2023
    Buyer
    Biosynth
    Target
    Cambridge Research Biochemicals
    Industry
    Biotechnology
    Location
    England, United Kingdom
    Type
    Buyout

    Biosynth, a Switzerland-based supplier of critical materials to the life science industry, has acquired Cambridge Research Biochemicals (CRB), a UK-based independent producer of custom peptides and antibody tools. The acquisition expands Biosynth's peptide and antibody capabilities in Europe, adding expertise in complex peptide chemistry, fluorescent dye labelling and custom antibody generation to its existing operations.

  • Biosynth Acquires Fitzgerald Industries Life Sciences Supply Business from Trinity Biotech for $30M
    April 20, 2023
    Buyer
    Biosynth, KKR, Ampersand Capital Partners
    Target
    Fitzgerald Industries (Benen Trading Ltd and Fitzgerald Industries International, Inc)
    Seller
    Trinity Biotech plc
    Industry
    Biotechnology
    Location
    Massachusetts, United States
    Type
    Divestiture

    Biosynth (backed by KKR and Ampersand Capital Partners) has agreed to acquire Trinity Biotech’s Fitzgerald life sciences supply business — comprising Benen Trading Ltd and Fitzgerald Industries International, Inc — for approximately $30 million in cash. Trinity Biotech pursued the divestiture to focus on diabetes care and decentralized diagnostics while reducing net debt; the Fitzgerald business generated about $12 million of revenue in 2022 and will be integrated into Biosynth’s global reagents and biologics platform.

  • Biosynth Carbosynth Acquires Pepscan
    July 4, 2022
    Buyer
    Biosynth Carbosynth
    Target
    Pepscan
    Industry
    Biotechnology
    Location
    Flevoland, Netherlands
    Type
    Addon

    Biosynth Carbosynth, a KKR- and Ampersand-backed supplier of materials to the life-sciences industry, has acquired Pepscan, a Netherlands-based peptide discovery, optimization and GMP peptide manufacturing specialist. The deal adds Pepscan’s proprietary CLIPS technology and epitope-mapping capabilities to Biosynth’s peptide capabilities (including vivitide) to form a new global Peptide division serving pharma, biotech, diagnostics and cosmetics customers.

  • Biosynth Carbosynth Acquires Aalto Bio Reagents
    May 26, 2022
    Buyer
    Biosynth Carbosynth
    Target
    Aalto Bio Reagents
    Industry
    Biotechnology
    Location
    Dublin, Ireland
    Type
    Addon

    Biosynth Carbosynth, a Swiss life‑sciences supplier, has acquired Aalto Bio Reagents, a Dublin‑based developer and provider of biological materials for in‑vitro diagnostics (IVD) and vaccine development. The deal strengthens Biosynth’s IVD and vaccine product portfolio and expands its capabilities to serve diagnostics and vaccine development customers worldwide.

  • KKR-backed Biosynth Carbosynth Acquires vivitide; Ampersand Rolls Over Stake
    March 17, 2022
    Buyer
    Biosynth Carbosynth, KKR
    Target
    vivitide
    Industry
    Biotechnology
    Location
    Massachusetts, United States
    Type
    Addon

    KKR has invested in Biosynth Carbosynth through its Health Care Strategic Growth Fund II, and Biosynth Carbosynth has acquired vivitide, a global provider of custom peptides and antibody services. Existing owner Ampersand Capital Partners rolled over its entire stake and will be a substantial minority shareholder in the combined global life‑sciences reagents and custom synthesis platform to accelerate geographic expansion, broaden capabilities, and expand the product portfolio.

Related Acquisition Pages

Biotechnology Buyers & Acquisitions 6 tracked deals by Biosynth. Pharmaceuticals Buyers & Acquisitions 1 tracked deal by Biosynth. Acquisitions in Massachusetts 2 tracked deals by Biosynth.

Related articles

Selling a company? Get in front of buyers like Biosynth

Turn tracked acquisition activity into an outreach-ready buyer list.

Find buyers like these →